公开(公告)号：US20240343796A1

公开(公告)日：2024-10-17

申请号：US18528157

申请日：2023-12-04

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo Attar ,  Francois Gaudet ,  Mark Tornetta ,  Alexey Teplyakov ,  Mark Mendonca ,  Suzanne Edavettal ,  Kodandaram Pillarisetti ,  Nathan Majewski ,  Yingzhe Li ,  Leopoldo L. Luistro, III ,  Diana Chin

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K39/0011 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.

公开(公告)号：US20240262900A1

公开(公告)日：2024-08-08

申请号：US18567197

申请日：2022-06-06

Applicant: JANSSEN BIOTECH, INC. ,  The Broad Institute, Inc. ,  The General Hospital Corporation

Inventor： Nathan Majewski ,  Ramnik Xavier ,  Thomas Sundberg ,  Gaochao Tian ,  Kyunghye Ahn Wisner ,  Holger Babbe

IPC: C07K16/18 ,  C07K1/22 ,  G01N33/68

CPC classification number: C07K16/18 ,  C07K1/22 ,  G01N33/6854 ,  G01N2440/14

Abstract: The present invention provides antigen binding domains that bind phosphorylated versions of CREB-regulated transcription coactivator 3 (CRTC3), polynucleotides encoding them, vectors, host cells, and methods of making and using them.

公开(公告)号：US11104724B2

公开(公告)日：2021-08-31

申请号：US16303666

申请日：2017-05-23

Applicant: NEW YORK UNIVERSITY ,  JANSSEN BIOTECH, INC.

Inventor： Victor J. Torres ,  Anthony S. Lynch ,  Peter T. Buckley ,  Nathan Majewski

IPC: C07K16/12

Abstract: The disclosure is directed to antibodies that bind to Staphylococcus aureus bi-component leukotoxins and/or gamma-hemolysins. Other aspects of the disclosure are directed to pharmaceutical compositions and diagnostic kits containing the leukotoxin and hemolysin antibodies, and therapeutic and diagnostic methods utilizing the leukotoxin and hemolysin antibodies.

公开(公告)号：US11884722B2

公开(公告)日：2024-01-30

申请号：US18157800

申请日：2023-01-20

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo Attar ,  Francois Gaudet ,  Mark Tornetta ,  Alexey Teplyakov ,  Mark Mendonca ,  Suzanne Edavettal ,  Kodandaram Pillarisetti ,  Nathan Majewski ,  Yingzhe Li ,  Leopoldo L. Luistro, III ,  Diana Chin

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K39/0011 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.